Efficacy and Safety of PEG-rhG-CSF in HSC Mobilization in 71 Normal Healthy Donors for Allogeneic Hematopoietic Stem Cell Transplantation.
10.19746/j.cnki.issn.1009-2137.2021.03.047
- Author:
Fang LIU
1
;
Guang-Cui HE
2
;
Hai YI
2
;
Ye-Cheng LI
2
;
Shan ZHANG
2
;
Rui DENG
2
;
Yan DENG
2
;
Si-Han LAI
2
;
Yi SU
2
Author Information
1. Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China,E-mail: 496109393@qq.com.
2. Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Antigens, CD34;
Female;
Graft vs Host Disease;
Granulocyte Colony-Stimulating Factor;
Hematopoietic Stem Cell Mobilization;
Hematopoietic Stem Cell Transplantation;
Humans;
Male;
Middle Aged;
Recombinant Proteins;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(3):951-956
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To retrospectively analyze the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in hematopoietic stem cell mobilization in 71 normal healthy donors for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS:From March 2018 to July 2019, 71 patients received allo-HSCT in The General Hospital of Western Theater Command were enrolled in the study, a single dose of PEG-rhG-CSF was injected subcutaneously at 12 mg to all the stem cell donors. After injection for 4 days, CD34
RESULTS:Seventy-one healthy stem cell donors included 39 males and 32 females with a median age of 38 (16-58) years old. The median number of CD34
CONCLUSION:For allo-HSCT donor mobilization, PEG-rh-G-CSF is effective, safe, and convenient, providing more options for HSC mobilization.
